All In Biotech

Drug Trial Radar · NCT06211036

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 563 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

563

Actual

Start

Jun 5, 2024

Primary completion

Apr 2, 2030

Study completion Apr 2, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Conditions

  • Extensive-Stage Small-Cell Lung Cancer
  • Small-Cell Lung Cancer

Interventions

  • TarlatamabDrug

    Intravenous (IV) infusion

  • DurvalumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OSTime frame: Up to approximately 3 years

Locations

219 sites in 29 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Center

    Mobile, Alabama

  • University of Southern California

    Los Angeles, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • University Cancer and Blood Center LLC

    Athens, Georgia

  • Emory University

    Atlanta, Georgia

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • University of Illinois Chicago

    Chicago, Illinois

  • Franciscan Health Indianapolis

    Indianapolis, Indiana

  • Our Lady of the Lake Cancer Institute

    Baton Rouge, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Allina Health System dba Allina Health Cancer Institute

    Saint Paul, Minnesota

  • Oncology Hematology Associates

    Springfield, Missouri

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Montefiore Medical Center - Bronx

    The Bronx, New York

  • Duke University

    Durham, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Oncology Hematology Care Incorporated

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Oncology Associates of Oregon, PC

    Eugene, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Allegheny Health Network

    Pittsburgh, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baptist Cancer Center Memphis Thoracic

    Memphis, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology - Dallas Fort Worth

    Dallas, Texas

  • US Oncology Research Investigational Products Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Virginia Oncology Associates

    Newport News, Virginia

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia

  • Swedish Cancer Institute

    Seattle, Washington

  • The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer

    La Rioja, Argentina

  • Hospital Britanico de Buenos Aires

    CABA, Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Capital Federal, Buenos Aires, Argentina

Showing 40 of 219 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.